Phase 1/2 study of combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for advanced non-squamous non-small cell lung cancer - Phase 1/2 study of combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for advanced non-squamous non-small cell lung cancer

Hiroshima Asa City Hospital0 sites35 target enrollmentMarch 8, 2015

Overview

No summary available.

Registry

who.int

Start Date

March 8, 2015

End Date

November 30, 2017

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Hiroshima Asa City Hospital

•1\) Squamous cell lung cancer 2\) History of Severe drug allergies. 3\) Double malignancies within 5 years 4\) Uncontrolled ascites, pleural effusion or cardiac effusion 5\) Current history of hemoptysis 6\-7\) High risk of bleeding or thrombus events 8\) Evidence of bleeding diathesis or coagulopathy 9\) Current or previous history of Pericardial effusion 10\) Superior vena cava syndrome 11\) Spinal cord compression 12\) Current or previous (within the last 1 year) history of cerebrovascular disease 13\) Traumatic fracture of unrecovery 14\) History of active infection 15\) Scheduled operation 16\) Antithrombotic agent 17\) Uncontrollable Gastrointestinal ulceration 18\) Current or previous (within the last 1 year)history of GI perforation 19\) Uncontrollable hypertension 20\) Severe cardiac disease 21\) Interstitial pneumonia or pulmonary fibrosis detectable on X ray 22\) With grade2 or more neuropathy 23\) Treatment history of bevacizumab 24\) Pregnancy, breastfeeding or suspected of being pregnant 25\) HBs positive patient 26\) Others judged by attending physician